# The Treatment of Unresectable Liver Cancer With E-TACE Combined With Donafenib：A Prospective, Single-arm, Multicenter, Observational Study

> **NCT07180459** · — · NOT_YET_RECRUITING · sponsor: **Xuhua Duan** · enrollment: 118 (estimated)

## Conditions studied

- Carcinoma
- Hepatocellular Carcinoma

## Interventions

- **PROCEDURE:** E-TACE
- **DRUG:** Donafenib

## Key facts

- **NCT ID:** NCT07180459
- **Lead sponsor:** Xuhua Duan
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10-10
- **Primary completion:** 2026-10-10
- **Final completion:** 2027-10-10
- **Target enrollment:** 118 (ESTIMATED)
- **Last updated:** 2025-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07180459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07180459, "The Treatment of Unresectable Liver Cancer With E-TACE Combined With Donafenib：A Prospective, Single-arm, Multicenter, Observational Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07180459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*